WO1999027955A3 - Treatment of established chronic infections and cancers - Google Patents

Treatment of established chronic infections and cancers Download PDF

Info

Publication number
WO1999027955A3
WO1999027955A3 PCT/GB1998/003583 GB9803583W WO9927955A3 WO 1999027955 A3 WO1999027955 A3 WO 1999027955A3 GB 9803583 W GB9803583 W GB 9803583W WO 9927955 A3 WO9927955 A3 WO 9927955A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
chronic infections
treatment
established chronic
substances
Prior art date
Application number
PCT/GB1998/003583
Other languages
French (fr)
Other versions
WO1999027955A2 (en
Inventor
Benjamin Michael Chain
Peter Charles Leonard Beverley
Alexander Hal Drakesmith
Deborah Antoinette O'neil
Original Assignee
Univ London
Benjamin Michael Chain
Peter Charles Leonard Beverley
Alexander Hal Drakesmith
Neil Deborah Antoinette O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London, Benjamin Michael Chain, Peter Charles Leonard Beverley, Alexander Hal Drakesmith, Neil Deborah Antoinette O filed Critical Univ London
Priority to AU13432/99A priority Critical patent/AU1343299A/en
Publication of WO1999027955A2 publication Critical patent/WO1999027955A2/en
Publication of WO1999027955A3 publication Critical patent/WO1999027955A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Abstract

It has been found that substances which cause acidification of the early endosome of dendritic cells cause the cells to present a broader range of epitopes than would otherwise be the case. Accordingly, the invention provides the use of such substances in the treatment of established chronic infections and cancers, as well as vaccines for the treatment of established chronic infections and cancers utilising such substances and/or dendritic cells and/or antigens specific to such established chronic infections and cancers.
PCT/GB1998/003583 1997-12-01 1998-12-01 Treatment of established chronic infections and cancers WO1999027955A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13432/99A AU1343299A (en) 1997-12-01 1998-12-01 Treatment of established chronic infections and cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9725480.9A GB9725480D0 (en) 1997-12-01 1997-12-01 Cytokines and their use in the treatment of established chronic infections and cancers
GB9725480.9 1997-12-01

Publications (2)

Publication Number Publication Date
WO1999027955A2 WO1999027955A2 (en) 1999-06-10
WO1999027955A3 true WO1999027955A3 (en) 1999-08-12

Family

ID=10822983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/003583 WO1999027955A2 (en) 1997-12-01 1998-12-01 Treatment of established chronic infections and cancers

Country Status (3)

Country Link
AU (1) AU1343299A (en)
GB (1) GB9725480D0 (en)
WO (1) WO1999027955A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241725A2 (en) * 1986-03-17 1987-10-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Improvements in and relating to vaccines
WO1995006077A2 (en) * 1993-08-27 1995-03-02 Sandoz Ltd. Polymeric matrices and their uses in pharmaceutical compositions
DE19535853A1 (en) * 1995-09-18 1997-03-20 Fraunhofer Ges Forschung Variants of the human recombinant interferon-gamma (rhu-IFN-gamma) with increased thermal stability
WO1997028808A1 (en) * 1996-02-12 1997-08-14 The Scripps Research Institute Methods of inhibiting leaderless protein export using cardiac glycosides or aglycones therefrom and derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241725A2 (en) * 1986-03-17 1987-10-21 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Improvements in and relating to vaccines
WO1995006077A2 (en) * 1993-08-27 1995-03-02 Sandoz Ltd. Polymeric matrices and their uses in pharmaceutical compositions
DE19535853A1 (en) * 1995-09-18 1997-03-20 Fraunhofer Ges Forschung Variants of the human recombinant interferon-gamma (rhu-IFN-gamma) with increased thermal stability
WO1997028808A1 (en) * 1996-02-12 1997-08-14 The Scripps Research Institute Methods of inhibiting leaderless protein export using cardiac glycosides or aglycones therefrom and derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAIN, B. M. ET AL: "Processing and presentation by dendritic cells. The role of th lysosome in antigen breakdown", REGUL. IMMUNE GENE EXPRESSION, [PROC. CONF.] (1986), MEETING DATE 1985, 207-19. EDITOR(S): FELDMANN, MARC;MCMICHAEL, ANDREW J. PUBLISHER: HUMANA, CLIFTON, N. J. CODEN: 55LJAC, XP002096617 *
DRAKESMITH H ET AL: "In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 DEC 8) 95 (25) 14903-8. JOURNAL CODE: PV3. ISSN: 0027-8424., United States, XP002096616 *
LUTZ ET AL.: "Intracellular routes and selective retention of antigens in mildly acidic cathepsin D/lysosome-associated membrane protein-1/MHC Class II-positive vesicles in immature dendritic cells", THE JOURNAL OF IMMUNOLOGY, vol. 159, 1997, pages 3707 - 3716, XP002096615 *

Also Published As

Publication number Publication date
WO1999027955A2 (en) 1999-06-10
AU1343299A (en) 1999-06-16
GB9725480D0 (en) 1998-01-28

Similar Documents

Publication Publication Date Title
IL201889A (en) Therapeutic compositions for the treatment of immune related disorders comprising antibodies that specifically recognize the nk 1.1 antigen or the cd56 antigen expressed by nk t cells
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2007067681A3 (en) Immunostimulatory compositions and methods
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
WO2006082406A3 (en) Human antibodies and proteins
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
NO20005672L (en) Attenuated Salmonella mutants constitutively expressing the Vi antigen
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
WO2005007673A3 (en) Immunogenic peptides
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
WO2002024739A3 (en) Spas-1 cancer antigen
WO2001096370A3 (en) Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
WO2006039533A3 (en) Bcr-abl imatinib resistance-associated peptides and methods of use thereof
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2003093298A3 (en) Immunogenic peptides
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
WO2002028889A3 (en) Haemophilus influenzae antigens and corresponding dna fragments
WO1999027955A3 (en) Treatment of established chronic infections and cancers
WO2004072094A3 (en) Hmgb1 modulator binding domain
WO2002026785A3 (en) Epitopes of virus hepatitis c specifically cd4+ t lymphocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA